BAC
Bank of America Corporation
BAC has slightly lower modeled downside risk, despite its lower overall score.
MORN
Morningstar, Inc.
MORN has the edge over BAC overall, supported by stronger valuation and stronger modeled upside.
BAC Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
BAC's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like BAC.
MORN Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| N/A | |
| N/A |
MORN's profitability is currently strong, and its revenue is stable. Free cash flow and net leverage aren't meaningful measures for financial services companies like MORN.
BAC PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 9.4x | $39.50 | -22% |
| Forward | 10x | $50.51 | — |
| Current | 12x | $50.51 | — |
| Fair | 13x | $53.81 | +6.5% |
| Expensive | 15x | $62.23 | +23% |
Historical ranges are pointers, not guarantees.
BAC's PE is in its fair range at 12x. If earnings grow as analysts expect, today's price would be 10x next year's earnings, in its cheap range.
MORN PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 17x | $246 | — |
| Current | 22x | $246 | — |
| Cheap | 26x | $298 | +21% |
| Fair | 48x | $549 | +123% |
| Expensive | 88x | $999 | +306% |
Historical ranges are pointers, not guarantees.
MORN has the edge over BAC in the historical PE scenario, which offers more potential upside but is not a forecast.
BAC Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect earnings and revenue growth for BAC, with profitability improving.
MORN Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for MORN, with profitability improving.
BAC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $4.92 | +17% |
| Q3 2026 | $4.19 | +14% |
| Q2 2026 | $4.34 | +27% |
| Q1 2026 | $4.02 | +20% |
| Q4 2025 | $3.81 | +19% |
| Q3 2025 | $3.66 | +33% |
| Q2 2025 | $3.41 | +20% |
| Q1 2025 | $3.35 | +16% |
| Q4 2024 | $3.21 | +4.2% |
BAC's earnings per share have climbed steadily: $4.19 over the past year, up 14% from the year before, and higher year over year for eight quarters in a row.
MORN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $14.12 | +24% |
| Q3 2026 | $11.41 | +30% |
| Q2 2026 | $10.52 | +12% |
| Q1 2026 | $9.78 | +9.8% |
| Q4 2025 | $8.87 | +3.4% |
| Q3 2025 | $8.80 | +16% |
| Q2 2025 | $9.40 | +64% |
| Q1 2025 | $8.91 | +80% |
| Q4 2024 | $8.58 | +161% |
MORN has the edge over BAC on earnings, with stronger typical year-over-year growth.
BAC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $30B | +6.7% |
| Q2 2026 | $31.6B | +19% |
| Q1 2026 | $30.3B | +11% |
| Q4 2025 | $31.2B | +23% |
| Q3 2025 | $28.1B | +11% |
| Q2 2025 | $26.5B | +4.3% |
| Q1 2025 | $27.4B | +6% |
| Q4 2024 | $25.3B | +15% |
BAC has the edge over MORN on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 30% | -3.7 points |
| Q2 2026 | 37% | +7.6 points |
| Q1 2026 | 34% | +4.7 points |
| Q4 2025 | 40% | +12 points |
| Q3 2025 | 34% | +4.8 points |
| Q2 2025 | 29% | -0.7 points |
| Q1 2025 | 30% | +1.5 points |
| Q4 2024 | 28% | +14 points |
BAC has the edge over MORN on profitability, with a higher operating margin.
MORN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $672.1M | +8.9% |
| Q2 2026 | $663.2M | +9.6% |
| Q1 2026 | $644.8M | +11% |
| Q4 2025 | $641.1M | +8.5% |
| Q3 2025 | $617.4M | +8.4% |
| Q2 2025 | $605.1M | +5.8% |
| Q1 2025 | $581.9M | +7.2% |
| Q4 2024 | $591M | +9.7% |
MORN's revenue has grown year over year every quarter since late 2020: $672M last quarter, up 8.9% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 25% | +4.2 points |
| Q2 2026 | 24% | +3.5 points |
| Q1 2026 | 24% | +4.6 points |
| Q4 2025 | 25% | -3.6 points |
| Q3 2025 | 21% | +0.4 points |
| Q2 2025 | 21% | +1.7 points |
| Q1 2025 | 20% | +2.6 points |
| Q4 2024 | 28% | +11 points |
MORN's operating margin was 25% last quarter, up 4.2 points from the same quarter a year ago, near the top of its range since 2019.
BAC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$6.5B | -114% |
| Q2 2026 | $29B | +$38.2B |
| Q1 2026 | $41.8B | +$44B |
| Q4 2025 | -$22.9B | -189% |
| Q3 2025 | $46.9B | +$84.2B |
| Q2 2025 | -$9.1B | -150% |
| Q1 2025 | -$2.2B | +$13.4B |
| Q4 2024 | $25.9B | -21% |
BAC's free cash flow was $41.4B over the past year, down 33% from the year before. Free cash flow isn't a meaningful measure for financial services companies like BAC.
MORN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $155.4M | -2.9% |
| Q2 2026 | $122.5M | +96% |
| Q1 2026 | $53.6M | -8.8% |
| Q4 2025 | $161.3M | +43% |
| Q3 2025 | $160.1M | +2.8% |
| Q2 2025 | $62.4M | -48% |
| Q1 2025 | $58.8M | -1.2% |
| Q4 2024 | $112.8M | +4.6% |
MORN's free cash flow was $493M over the past year, up 25% from the year before. Free cash flow isn't a meaningful measure for financial services companies like MORN.
BAC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1% | -72M shares |
| 1 year | -5.3% | -405M shares |
| 3 years | -11% | -854M shares |
| 5 years | -15% | -1.3B shares |
| Available history | -24% | -2.2B shares |
BAC has 7.2B diluted shares, down 5.3% from a year ago, with $25.6B in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $6B |
| Q2 2026 | $6B |
| Q1 2026 | $7.2B |
| Q4 2025 | $6.3B |
| Q3 2025 | $5.3B |
| Q2 2025 | $5.3B |
| Q1 2025 | $4.5B |
| Q4 2024 | $3.5B |
BAC spent $25.6B buying back its own shares over the past year, up 37% from the year before.
MORN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.8% | -300K shares |
| 1 year | -11% | -4.5M shares |
| 3 years | -12% | -5.1M shares |
| 5 years | -13% | -5.6M shares |
| Available history | -13% | -5.5M shares |
MORN has the edge over BAC on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $100M |
| Q2 2026 | $100M |
| Q1 2026 | $300M |
| Q4 2025 | $395.3M |
| Q3 2025 | $170.1M |
| Q2 2025 | $112M |
| Q1 2025 | $109.6M |
| Q4 2024 | $11.6M |
MORN spent $895M buying back its own shares over the past year, up 122% from the year before.
BAC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 6.4x | High |
| Q2 2026 | 6.7x | High |
| Q1 2026 | 7.1x | High |
| Q4 2025 | 7.7x | High |
| Q3 2025 | 8.3x | High |
| Q2 2025 | 8.8x | High |
| Q1 2025 | 8.6x | High |
| Q4 2024 | 9.0x | High |
BAC's net debt is about 6.4 years of its operating earnings (EBITDA), down from 8.3 years a year ago. Net leverage isn't a meaningful measure for financial services companies like BAC.
MORN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.4x | Healthy |
| Q2 2026 | 1.6x | Healthy |
| Q1 2026 | 1.6x | Healthy |
| Q4 2025 | 0.8x | Very low |
| Q3 2025 | 0.5x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.4x | Very low |
| Q4 2024 | 0.3x | Very low |
MORN has the edge over BAC on leverage, with a lower net debt burden relative to earnings.
BAC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.1 | Neutral |
| Stochastic | 4.9 | Oversold |
BAC's weekly RSI is 37 (neutral) and its Stochastic is 5 (oversold).
MORN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 67.0 | Neutral |
| Stochastic | 94.7 | Overbought |
MORN's weekly RSI is 67 (neutral) and its Stochastic is 95 (overbought).
BAC PE vs Financial Services Sector
| Metric | BAC | Sector median | Relative |
|---|---|---|---|
| PE | 12x | 13x | 7.5% below |
| PE % | 40 | 63 | 23 pts below |
BAC has the edge over MORN on valuation relative to its sector.
MORN PE vs Financial Services Sector
| Metric | MORN | Sector median | Relative |
|---|---|---|---|
| PE | 22x | 13x | 66% above |
| PE % | 11 | 63 | 52 pts below |
MORN is trading at 22x earnings, a 66% premium to the Financial Services sector's median of 13x.
BAC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $52.1 | 3% below |
| 20 week MA | $57.8 | 13% below |
| 50 week MA | $54.7 | 7.7% below |
| 100 week MA | $50.5 | 0% below |
| 200 week MA | $42.5 | 19% above |
BAC has fallen below most of its moving averages, though it's still 19% above its 200-week average.
MORN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $216.6 | 14% above |
| 20 week MA | $202.4 | 22% above |
| 50 week MA | $191.9 | 28% above |
| 100 week MA | $236.4 | 4.1% above |
| 200 week MA | $251.9 | 2.3% below |
MORN has the edge over BAC on trend strength, trading above more of its moving averages.
BAC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $35.4 | $30.0 | -15% |
| 2021 | $30.0 | $44.4 | +48% |
| 2022 | $44.4 | $32.5 | -27% |
| 2023 | $32.5 | $33.7 | +3.7% |
| 2024 | $33.7 | $44.3 | +32% |
| 2025 | $44.3 | $56.2 | +27% |
| 2026 YTD | $56.2 | $50.5 | -10% |
BAC has finished higher in four of the last six years. It's down 10% so far in 2026.
MORN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $152.0 | $222.3 | +46% |
| 2021 | $222.3 | $339.5 | +53% |
| 2022 | $339.5 | $213.5 | -37% |
| 2023 | $213.5 | $286.2 | +34% |
| 2024 | $286.2 | $339.8 | +19% |
| 2025 | $339.8 | $219.1 | -36% |
| 2026 YTD | $219.1 | $246.1 | +12% |
MORN has the edge over BAC on returns for 2026, with the stronger performance.